Insulet (PODD) Stock Forecast & Price Target

Insulet is supported by a differentiated Omnipod franchise that has expanded to more than 600,000 insulin-dependent patients worldwide, with Q2 revenue up 23% cc to $801.7 million and adjusted EPS of $1.66, both ahead of expectations. Its growth case is reinforced by strong U.S. Omnipod sales of $544.1 million, OUS Omnipod growth of 32.9% cc, and improved profitability, with gross margin at 72.9% and operating margin at 19.3%. The outlook remains constructive because management is still targeting 20% CAGR revenue growth, 100 bps of annual adjusted operating margin expansion through 2028, and over $1 billion of R&D investment to deepen product leadership and expand into adjacent opportunities.

Insulet is facing a negative setup because lower U.S. Type 2 utilization and retention are pressuring growth, with U.S. Omnipod revenue guidance cut to 17% to 19% and implied 4Q growth falling to roughly 8% to 15% y/y. Management’s revised 2026 outlook points to a sharper deceleration in the U.S. through 2H26-2027, while emerging tubeless competition and trialing in 2027+ threaten share and keep estimates moving lower. Although total company growth is still projected around 21% to 23% and adjusted EPS growth above 30%, the suspended long-range plan, recalls, and damaged credibility make the valuation vulnerable to an extended period of range-bound performance.